Can-Fite BioPharma announced that partner Vetbiolix completed enrollment in a Phase 2 osteoarthritis study in dogs with Piclidenoson, with top-line data expected in Q3 2026.
Key takeaways
Vetbiolix completed enrollment in a Phase 2 study of Piclidenoson for treating osteoarthritis in 118 dogs.
Top-line results for the Phase 2 study are expected in the third quarter of 2026.
Can-Fite is entitled to upfront, milestone, and royalty payments worth up to $325 million under the agreement with Vetbiolix.
Vetbiolix is funding all development costs and is responsible for all development and regulatory activities.
The study is a randomized, double-blind, placebo-controlled, dose-ranging trial with a 90-day treatment period.